324 related articles for article (PubMed ID: 17288690)
1. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
Cornes P; Coiffier B; Zambrowski JJ
Curr Med Res Opin; 2007 Feb; 23(2):357-68. PubMed ID: 17288690
[TBL] [Abstract][Full Text] [Related]
2. Phase III clinical trials with darbepoetin: implications for clinicians.
Glaspy J
Best Pract Res Clin Haematol; 2005; 18(3):407-16. PubMed ID: 15792914
[TBL] [Abstract][Full Text] [Related]
3. Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting.
Gascón P
Eur J Cancer; 2005 Nov; 41(17):2601-12. PubMed ID: 16230006
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietic agents in anaemic patients with cancer: a retrospective observational survey of epoetin alpha, epoetin beta and darbepoetin alpha use in routine clinical practice.
Pujade-Lauraine E; Richard AJ; Sapède C; Hayward C
Oncol Rep; 2005 Oct; 14(4):1037-44. PubMed ID: 16142369
[TBL] [Abstract][Full Text] [Related]
5. Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns.
Stasi R; Amadori S; Littlewood TJ; Terzoli E; Newland AC; Provan D
Oncologist; 2005 Aug; 10(7):539-54. PubMed ID: 16079321
[TBL] [Abstract][Full Text] [Related]
6. Anemia in cancer and critical care patients: pharmacoeconomic considerations.
Reeder CE
Am J Health Syst Pharm; 2007 Feb; 64(3 Suppl 2):S22-7; quiz S28-30. PubMed ID: 17244883
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
Case AS; Rocconi RP; Kilgore LC; Barnes MN
Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
[TBL] [Abstract][Full Text] [Related]
8. Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins.
Oberhoff C
Support Care Cancer; 2007 Jun; 15(6):603-611. PubMed ID: 17277926
[TBL] [Abstract][Full Text] [Related]
9. Anemia therapy: individual benefit and societal cost.
Denton TA; Diamond GA; Matloff JM; Gray RJ
Semin Oncol; 1994 Apr; 21(2 Suppl 3):29-35. PubMed ID: 8202723
[TBL] [Abstract][Full Text] [Related]
10. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P;
Eur J Cancer; 2007 Jan; 43(2):258-70. PubMed ID: 17182241
[TBL] [Abstract][Full Text] [Related]
11. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
Cersosimo RJ; Jacobson DR
Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
[TBL] [Abstract][Full Text] [Related]
12. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.
Glaspy J
Semin Hematol; 1997 Jul; 34(3 Suppl 2):20-6. PubMed ID: 9253780
[TBL] [Abstract][Full Text] [Related]
13. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
[TBL] [Abstract][Full Text] [Related]
14. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
[TBL] [Abstract][Full Text] [Related]
15. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
Song X; Long SR; Marder WD; Sullivan SD; Kallich J
Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
[TBL] [Abstract][Full Text] [Related]
16. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
Voils SA; Harpe SH; Brophy GM
Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
[TBL] [Abstract][Full Text] [Related]
17. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
[TBL] [Abstract][Full Text] [Related]
18. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.
Stevenson JG; Natale JJ
Pharmacotherapy; 2007 Mar; 27(3):434-46. PubMed ID: 17316154
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
Corapcioglu F; Aksu G; Basar EZ; Demirel A; Oncel S; Mutlu A
Pediatr Hematol Oncol; 2008 Sep; 25(6):509-21. PubMed ID: 18728970
[TBL] [Abstract][Full Text] [Related]
20. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]